Brickell is focused on the development of novel and differentiated therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our current pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, acne, psoriasis, atopic dermatitis and androgenic alopecia.


Latest News

[October 19, 2016]

Newly Published Data in the Archives of Dermatological Research Reveal That Hyperhidrosis is More Prevalent, Severe and Socially Debilitating than Previously Reported.


[March 7, 2016]

Brickell's Phase 2b Study Results for BBI-4000 Presented at the Late-breaking Research Forum during the 74th American Academy of Dermatology Annual Meeting.